Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A51R2 + A51R3
- Development stage
- Unknown
- Lead developer
- AJU Pharm
01
Overview
A51R2 + A51R3 is a combination drug investigated in Phase 3 clinical trials for the treatment of **Type 2 diabetes mellitus** in patients with inadequate glycemic control[1][2]. The products referred to as A51R2 and A51R3 are not defined by nonproprietary names in the available sources. The combination was compared to other regimens, including AJU-A51 (a fixed-dose combination of dapagliflozin and linagliptin)[1][2]. The mechanism of action and molecular identities of A51R2 and A51R3 are not explicitly stated in available clinical trial records or summaries. The developer and sponsor for clinical trials involving this combination is Aju Pharm[2].
Beyond the preview
Go deeper on A51R2 + A51R3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A51R2 + A51R3.